Founded in Menlo Park, California, Synthego is a biotechnology company focused on making CRISPR gene editing more accessible and efficient. The company's core mission is to accelerate the pace of scientific discovery by providing high-quality, reliable tools for genome engineering. Synthego offers a range of products, including multi-guide RNA kits and custom-made edited cells, designed to simplify and streamline the CRISPR process for researchers. Their market focus includes academic institutions, pharmaceutical companies, and biotech firms primarily in California but with a growing global presence.

Notable affiliated individuals include co-founders Paul and Michael Dabrowski, who have backgrounds in engineering and software development. Synthego has attracted significant investment from prominent venture capital firms such as 8VC and Founders Fund. Key achievements include the development of automated platforms for RNA synthesis and cell engineering, which have significantly reduced the time and cost associated with CRISPR research. Overall, Synthego has made a substantial impact on the field of genetic engineering by democratizing access to advanced genome editing technologies.